본문 바로가기
KERD
논문KCI 등재

Phase II Study of Consolidation Chemotherapy after Adjuvant or Primary Concurrent Chemoradiation Using Paclitaxel and Carboplatin to Treat High-Risk Early-Stage or Locally Advanced Cervical Cancer

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

주제분류의학일반

초록

Purpose This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. Materials and Methods From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO)stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m^2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. Results The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60%in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports,consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. Conclusion Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.

Abstract

Purpose This study investigated the efficacy and toxicity associated with consolidation chemotherapy using paclitaxel and carboplatin after concurrent chemoradiation (CCR) in cervical cancer patients. Materials and Methods From a total of 37 patients, 19 with International Federation of Gynecology and Obstetrics (FIGO)stage IB1-IIA cervical cancer (group 1) underwent surgery followed by consolidation chemotherapy after CCR, and 18 with stage IIB-IVA disease (group 2) received consolidation chemotherapy after primary CCR. Three cycles of chemotherapy using paclitaxel (135 mg/m^2) and carboplatin (AUC 5.0) were administered every 3 weeks for CCR therapy, and three cycles of consolidation chemotherapy using paclitaxel (175 mg/m2) and carboplatin (AUC 5.0) were used every 3 weeks after CCR. Results The complete and partial response rates were 77.8% and 22.2% in group 2. Moreover, the 3-year progression-free and overall survival rates were 62.7% and 90.9% in group 1, and 51.9% and 60%in group 2, respectively. The most common grade 3 or 4 hematologic toxicities observed were leukopenia (group 1, 10.5%; group 2, 13.0%) and neutropenia (group 1, 7.0%; group 2, 14.8%), and grade 3 or 4 diarrhea (group 1, 1.8%) and febrile illness (group 2, 1.9%) were the most frequently observed non-hematologic toxicities. When we compared these results with previous reports,consolidation chemotherapy after CCR using paclitaxel and carboplatin revealed a relatively lower complete response rate (77.8% vs. 87-100%, respectively) and shorter progression-free survival (51.9-62.7% vs. 81-86%, respectively) and overall survival (60-90.9% vs. 81-95%, respectively) in spite of similar toxicity findings. Conclusion Due to low efficacy results, consolidation chemotherapy using paclitaxel and carboplatin after CCR is not a feasible treatment regimen for high-risk early-stage or locally advanced cervical cancer.

참고문헌 (23)

  1. 서동훈, "Major clinical research advances in gynecologic cancer in 2010", Journal of Gynecologic Oncology, 21(4), pp.209~218 (2010), 대한부인종양학회
  2. [URL]
  3. Green JA, "Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix : a systematic review and meta-analysis", Lancet, 358, pp.781~786 (2001)
  4. Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer", N Engl J Med, 340, pp.1144~1153 (1999)
  5. Petera J, "External beam radiotherapy and high-dose brachytherapy combined with cisplatin and paclitaxel in patients with advanced cervical carcinoma", Gynecol Oncol, 99, pp.334~338 (2005)
  6. 김영석, "Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer", Gynecologic Oncology, 108(1), pp.195~200, Academic Press
  7. Vrdoljak E, "Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix : results of a phase II study", Int J Radiat Oncol Biol Phys, 61, pp.824~829 (2005)
  8. Chung YL, "Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer : a phase I", II study, 2005, pp.97, 126~135
  9. Choi CH, "Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer : preliminary results", Int J Radiat Oncol Biol Phys, 68, pp.817~822 (2007)
  10. Ozols RF, "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer : a Gynecologic Oncology Group study", J Clin Oncol, 21, pp.3194~3200 (2003)
  11. Piccart MJ, "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer : three-year results", J Natl Cancer Inst, 92, pp.699~708 (2000)
  12. Saito I, "A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer : Gynecologic Cancer Study Group", Japan Clinical Oncology Group Study(JCOG0505), 2010, pp.40, 90~93
  13. [URL]
  14. Kim K, "Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer", Gynecol Oncol, 101, pp.398~402 (2006)
  15. Lee MY, "Concurrent radiotherapy with paclitaxel", carboplatin chemotherapy as a definitive treatment for squamous cell carcinoma of the uterine cervix, 2007, pp.104, 95~99
  16. Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)
  17. de Vos FY, "Paclitaxel and carboplatin concurrent with radiotherapy for primary cervical cancer", Anticancer Res, 24, pp.345~348 (2004)
  18. Peters WA 3rd, "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix", J Clin Oncol, 18, pp.1606~1613 (2000)
  19. Zhang MQ, "Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix : preliminary results of a phase II study", Int J Radiat Oncol Biol Phys, 78, pp.821~827 (2010)
  20. Wang X, "High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer", Cochrane Database Syst Rev, (7), pp.007563~ (2010)
  21. Monk BJ, "Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma : a Gynecologic Oncology Group study", J Clin Oncol, 27, pp.49~55 (2009)
  22. Kitagawa R, "Phase II trial of paclitaxel and carboplatin in patients with recurrent or metastatic cervical carcinoma", J Clin Oncol, 22(14S), pp.5048~ (2004)
  23. Higgins R, "Concurrent carboplatin and paclitaxel with pelvic radiation therapy in the primary treatment of cervical cancer", Am J Obstet Gynecol, 197, pp.205.e1~205.e5 (2007)

관련 논문AI추천

고위험 자궁경부암의 수술 후 보조요법으로서 Paclitaxel과Carboplatin 동시 항암화학방사선요법의 효능과 안전성강순범, 김재원, 박노현, 송용상, 이효표, 조현일대한산부인과학회 · Obstetrics & Gynecology Science2004 · 제47권 제5호Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer김성한, 김원규, 김흥열, 이천준, 이태연, 정이조대한산부인과학회 · Obstetrics & Gynecology Science2013 · 제56권 제01호Neoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancy공태욱, 손주혁, 유희석, 이용희, 이은주, 장석준대한산부인과학회 · Obstetrics & Gynecology Science2014 · 제57권 제06호Impact of Chemoradiation on Prognosis in Stage IVB Cervical Cancer with Distant Lymphatic Metastasis김재원, 김태헌, 김학재, 김희승, 박노현, 송용상, 이응석, 정현훈대한암학회 · Cancer Research and Treatment2013 · 제45권 제3호Impact of hematologic toxicities during concurrent chemoradiation for cervical cancerAlison K. Yoder, Claire Mach, Feiya Shi, Matthew L Anderson, Michelle S Ludwig, Shraddha Dalwadi, Tracilyn R Hall대한산부인과학회 · Obstetrics & Gynecology Science2022 · 제65권 제2호Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation (CCRT) for Cervical Cancer on Overall Survival박원, 김병기, 김보미, 김태중, 노경원, 배덕수, 이유영, 이정원, 조원경, 최철훈대한암학회 · Cancer Research and Treatment2022 · 제54권 제1호

이 간행물의 다른 논문 (10건)